SCHEMBL4044909

SCHEMBL4044909

C#CC(C)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9084961 1.00
SCHEMBL2644262 1.00
SCHEMBL12769948 0.77
SCHEMBL10402929 0.76
SCHEMBL8823325 0.76
SCHEMBL9180674 0.76 TSHR (0.30)
SCHEMBL5157290 0.74
SCHEMBL14969524 0.74
SCHEMBL751417 0.74
SCHEMBL2192426 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814462-B2 Functionalized cyclic polymers and methods of preparing same UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-11-14 US claimed
US-20220056167-A1 Functionalized Cyclic Polymers and Methods of Preparing Same NATIONAL SCIENCE FOUNDATION 2022-02-24 US claimed
WO-2025202022-A9 ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 BAYER AKTIENGESELLSCHAFT (DE) 2025-12-26 WO disclosed
WO-2025202022-A1 ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 BAYER AKTIENGESELLSCHAFT (DE) 2025-10-02 WO disclosed
CN-113166177-B Boron-containing PDE4 inhibitors 辉瑞公司 2024-09-03 CN disclosed
EP-3861001-B1 BORON CONTAINING PDE4 INHIBITORS PFIZER (US) 2023-12-13 EP disclosed
US-11814462-B2 Functionalized cyclic polymers and methods of preparing same UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-11-14 US disclosed
US-20230148402-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2023-05-11 US disclosed
US-20230051031-A1 MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON SEPIOLITE FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2023-02-16 US disclosed
US-20230034883-A1 MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON NATURAL CLAYS FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION CONSIGLIO NAZIONALE DELLE RICERCHE (60%) (IT) 2023-02-02 US disclosed
US-11559538-B2 Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors PFIZER INC. (US) 2023-01-24 US disclosed
US-20030055084-A1 Pharmaceutical compounds and methods of use thereof MILLENNIUM PHARMACEUTICAL, INC. 2003-03-20 US disclosed
WO-2003011848-A1 BENZOHETEROCYCLES AS LIPOXYGENASE INHITIBORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-02-13 WO disclosed
US-20020169163-A1 Piperazine derivatives HOFFMAN-LA ROCHE INC. 2002-11-14 US disclosed
US-6201016-B1 IMMUNOSUPPRESSANT AS 5-LIPOXYGENASE INHIBITOR AND/OR AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONIST CYTOMED INCORPORATED 2001-03-13 US disclosed
EP-0770064-A4 COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS CYTOMED INC (US) 1998-01-14 EP disclosed
US-5681966-A ENANTIOMERICALLY ENRICHED DISUBSTITUTED TETRAHYDROFURANS, TETRAHYDROTHIOPHENES ACT AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS OR 5-LIPOXYGENASE INHIBITORS CYTOMED, INC. (US) 1997-10-28 US disclosed
EP-0770064-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS CYTOMED, INC. (US) 1997-05-02 EP disclosed
US-5587491-A Method for the synthesis of bis-tetrahydrofuranyl Annonaceous acetogenins REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1996-12-24 US disclosed
WO-1996000212-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS CYTOMED, INC. (US) 1996-01-04 WO disclosed